

| | |
|-----------------------------|--|
| Title | Quality indicators for hospital antimicrobial stewardship programmes: a systematic review |
| Authors | O'Riordan, Frank;Shiely, Frances;Byrne, Stephen;Fleming, Aoife |
| Publication date | 2021-03-31 |
| Original Citation | O'Riordan, F., Shiely, F., Byrne, S. and Fleming, A. (2021) 'Quality indicators for hospital antimicrobial stewardship programmes: a systematic review', Journal of Antimicrobial Chemotherapy, 76(6), pp. 1406-1419. doi: 10.1093/jac/dkab034 |
| Type of publication | Article (peer-reviewed) |
| Link to publisher's version | 10.1093/jac/dkab034 |
| Rights | © 2021, the Authors. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. |
| Download date | 2024-04-19 08:09:45 |
| Item downloaded from | https://hdl.handle.net/10468/11540 |



UCC

University College Cork, Ireland
 Coláiste na hOllscoile Corcaigh

1 **Quality indicators for hospital antimicrobial stewardship programmes: a systematic review.**

2 F. O’Riordan^{1,2*}, F. Shiely^{3,4}, S. Byrne², A. Fleming^{2,1}

3 1. Pharmacy Department, Mercy University Hospital, Grenville Place, Cork, Ireland

4 2. Clinical Pharmacy Research Group, School of Pharmacy, University College Cork, Cork, Ireland.

5 3. HRB Clinical Research Facility Cork, Mercy University Hospital, Grenville Place, Cork, Ireland

6 4. School of Public Health, University College Cork, Cork, Ireland

7 *corresponding author: email: fmoriordan@hotmail.com, Telephone:00353 21 4935632

8 Background

9 Measuring the quality and effectiveness of antimicrobial stewardship (AMS) programmes with
10 quality indicators (QIs) is an area of increasing interest. We conducted a systematic review to
11 identify QIs of AMS programmes in the hospital setting and critically appraise their methodological
12 quality.

13 Methods

14 We searched the Cochrane Library, PubMed, MEDLINE, EMBASE, CINAHL, Scopus/web of science
15 databases and the grey literature for studies which defined and/or described the development
16 process and characteristics of the QIs developed. The Appraisal of Indicators through Research and
17 Evaluation (AIRE) instrument was used to critically appraise the methodological quality of the QI
18 sets.

19 Results

20 We identified 16 studies of QI sets consisting of 229 QIs. The QI sets addressed a broad range of
21 areas of AMS in the hospital setting and consisted of 75% process indicators, 24% structural
22 indicators and 1% outcome indicators. There was a wide variation in the information and level of
23 detail presented describing the methodological characteristics of the QI sets identified.

24 Conclusion

25 The QIs identified in this study focused on process and structural indicators with few outcome
26 indicators developed, a major deficiency in this area. Future research should focus on the
27 development of outcome indicators or the use of process or structural indicators linked to outcomes
28 to assess AMS. Testing of the QIs in practice is an essential methodological element of the QI
29 development process and should be included in the QI development study or as planned validation
30 work.

31 Introduction

32 Antimicrobial resistance (AMR) is a major threat to public health contributing to increasing rates of
33 illness, death and significant economic costs.^{1,2} Antimicrobial stewardship (AMS) programmes have
34 been implemented to address the escalating threat to human health posed by AMR. AMS aims to
35 optimise antimicrobial use in order to maximise the probabilities of clinical cure or prevention of
36 infection while minimising unintended consequences such as toxicity and the selection of
37 pathogenic organisms (e.g. *Clostridioides difficile*).³ AMS is an important element of patient safety
38 and a widely applied quality improvement initiative.⁴ Implementation guidelines for AMS
39 programmes place a strong emphasis on improving the quality of antimicrobial use⁵ and evaluation
40 of AMS programmes, but do not identify specific indicators of performance.⁶

41 Measuring the quality of healthcare can be achieved by using quality indicators (QIs). QIs are defined
42 as ‘measurable elements of practice performance for which there is evidence or consensus that they
43 can be used to assess the quality of care provided’.⁷ QIs can measure the quality of care by
44 examining the structures, processes, and outcomes of care.^{8,9} This acknowledges that good
45 structures increase the likelihood of good processes, and good processes increase the likelihood of
46 good outcomes.⁸

47 To ensure QIs provide accurate measures of quality, they must adhere to certain quality
48 requirements. QIs should be evidence based,¹⁰ but in situations where scientific evidence is lacking,
49 QIs can be defined by an expert panel of professionals using consensus techniques such as the
50 Delphi technique or RAND/UCLA (Research and Development Corporation) (University of California,
51 Los Angeles) appropriateness method.¹¹ The systematic method of combining scientific evidence and
52 expert opinion is the most rigorous method to develop QIs as it provides face and content validity.¹²
53 Furthermore QIs should be tested during their development¹² to demonstrate they are acceptable to
54 users (those being assessed and their assessors), feasible to measure, reliable and reproducible,

55 sensitive to change and validated so as to ensure that they will produce consistent and credible
56 measures of the quality of care.^{9 13}

57 Cost savings were among the initial incentives for hospitals to implement AMS programmes.¹⁴
58 However, this is injudicious because factors such as antimicrobial patent expiry, drug shortages and
59 the increasing prevalence of multi-drug resistant organisms requiring the use of more expensive
60 agents, all of which are beyond the control of an AMS programme. Thus cost savings alone is an
61 unreliable indicator of performance¹⁵ and makes a further case for measures to demonstrate the
62 clinical and economic values of AMS programmes.¹⁶ Measuring the effectiveness of AMS
63 programmes is thus important and is an area of increasing interest.¹⁷

64 The purpose of this systematic review is to identify existing QIs of AMS programmes in the hospital
65 setting, describe the methodological approaches used in their development, differentiate between
66 the types of indicators (structure, process or outcome), and critically appraise the methodological
67 quality of the identified QI sets using the Appraisal of Indicators through Research and Evaluation
68 (AIRE) instrument.

69 **Methods**

70 This study was conducted and reported according to the Preferred Reported Items for Systematic
71 Reviews and Meta-analysis (PRISMA).¹⁸

72 Search strategy

73 An initial search for other systematic reviews of QIs for AMS programmes in hospitals identified two
74 existing reviews.^{19 20} However, neither study undertook a quality assessment of the methodological
75 development of the QIs sets identified.

76 The search strategy aimed to identify publications concerning the development, testing or
77 implementation of indicators of the quality of AMS programmes and antimicrobial prescribing. The
78 Cochrane Library, PubMed, MEDLINE, EMBASE, CINAHL and Scopus/web of science databases were
79 searched. A manual search of the grey literature, including conference proceedings, reports and
80 thesis, was also conducted to find information regarding QI development initiatives which were not
81 published in peer-reviewed journals. The reference lists of full text articles identified were screened
82 to find other relevant studies. No language restrictions were imposed on the search algorithms.
83 Searches were limited to studies of humans. The search period ran from the inception of the
84 databases to the 1/12/2019 and the search was repeated on the 26/9/2020. The search terms were:

85

Anti-infective agents [MeSH] OR
Antibiotic prophylaxis [MeSH] OR
Antibiotic* [tiab] OR
Antimicrobial*[tiab] OR
Anti microbial*[tiab] OR
Anti infective*[tiab] OR
Antiinfective*[tiab] OR
Antibacterial*[tiab] OR
Anti bacterial*[tiab]

AND

Quality indicators, health care
[MeSH] OR
Quality indicator*[tiab] OR
Quality measure*[tiab] OR
Quality metric*[tiab] OR
Quality criteria[tiab] OR
Qualitative measure*[tiab] OR
Quality improvement [ti]

95 Inclusion criteria and study selection

96 Studies were eligible for inclusion if they met the following criteria:

- 97 1. The study defines and/or describes the development process and characteristics of the QIs
98 developed.
- 99 2. The identified QIs are applicable to adult patients in the hospital setting and related to the
100 overall assessment of AMS programmes or the assessment of AMS related to specific clinical
101 indications (e.g. sepsis, Community Acquired Pneumonia (CAP), Urinary Tract Infections
102 (UTIs)) or settings (e.g. ICU).
- 103 3. Where the set of QIs were updated the publication describing the updated QIs was selected
104 for inclusion.

105 Exclusion Criteria

- 106 1. Editorials, letters to the editor, comments, and narrative case reports.
- 107 2. Publications describing the application of existing QIs in clinical practice or reviews of sets of
108 QIs.

109 Following completion of the database searches, the identified references were entered into a
110 bibliographical database and duplicates removed. The title and abstracts of these references were
111 screened for relevance (keywords in the title, abstract or study subject headings) by one reviewer
112 (FOR). The resulting abstracts were included for full text review by two reviewers (FOR and AF)
113 independently, according to inclusion criteria, and any disagreements resolved by consensus. If no
114 consensus could be reached a third reviewer (FS) was consulted. The reference lists of the selected
115 publications were then screened for other relevant studies that had not been identified in the
116 electronic database searches.

117

118 Data extraction

119 A data extraction form was designed and used to extract relevant information about the QIs from
120 the included articles (Supplementary data SD1).

121 Categorising and grouping of the extracted QIs

122 The QIs extracted were categorised as structural, process or outcome QIs, classified by theme within
123 each category and where there was conceptual, or content overlap in the description of the QI they
124 were grouped together as agreed on by all authors.

125 Critical appraisal

126 The AIRE instrument²¹ was used to appraise the methodological quality of the QI sets included in this
127 study. It is a validated instrument which has been designed to assess the quality of QIs.²² It
128 addresses four quality domains of a QI and consists of 20 items which are applied to each completed
129 set of QIs. Three domains address the methodological quality of QIs and were used in this review:
130 'Stakeholder involvement', 'Scientific evidence' and 'Additional evidence, formulation and usage'.
131 The fourth domain: 'purpose, relevance and organisational context' reflect the relevance of the QIs
132 within a particular context rather than methodological quality so was not used in this review. Table 1
133 contains the AIRE domains and items applied in this study. Each item consists of a statement which
134 is scored according to a 4-point Likert scale (1 'strongly disagree or no information provided' to 4
135 'strongly agree'(confident that the criterion has been fulfilled)). Scores for each domain were
136 calculated by summing up the scores for each individual item in a category and standardising the
137 total as a percentage of the maximum possible score for the domain. The AIRE instrument was
138 completed by two reviewers independently (FOR and AF or FS) for each complete QI set rather than
139 for each QI individually as most studies gave general information for the QI sets concerning
140 development and supporting evidence. (Further details about the AIRE instrument and its scoring
141 system are contained in Supplementary data SD2). The scores for each domain are independent and
142 should not be aggregated into a single total quality score. The standardised scores for each domain

143 range from 0% to 100%, with a score of 50% or higher indicating a higher methodological quality for
144 each domain of the instrument.²¹

145 Inter-rater reliability between reviewers

146 The inter-rater reliability between the three reviewers was assessed by comparing the individual
147 scores per AIRE item for two separate publications included in this study by calculating the weighted
148 Cohen's Kappa. The inter-rater reliability between (FOR and AF) and (FOR and FS) amounted to 0.69
149 and 0.73 respectively. (Supplementary data SD3). A Cohen's Kappa of between 0.61 and 0.80 is
150 considered substantial agreement.

Results

Search results

The PRISMA flow diagram of the study selection process and reasons for exclusion is seen in Figure 1. The systematic literature search identified 4833 potentially relevant studies. Following screening of titles and abstracts, 85 potentially relevant studies were selected for full-text screening. Six additional studies were included in the full text screening after reference screening of the selected publications. 75 studies were excluded and 16 publications of QI sets were included in this review.

Study characteristics

Table 2 presents an overview of the studies included in this review. Most included studies originated from Europe (11) followed by the UK (2), the USA (1) and Indonesia (1), one further study involved an assessment of USA and European hospitals.

The most common study design used in QI development involved a combination of a literature review (8) or review of clinical evidence and/or clinical guidelines (4), and, a consensus process [RAND modified Delphi (7), modified Delphi (2), RAND/UCLA appropriateness (2) or Delphi (1)] involving national or international multi-disciplinary expert panels. Other techniques included: a literature review and consensus, a multi-disciplinary team consensus, a national target for *Clostridioides difficile* and a national working group evidence base review.

The 16 QI sets addressed a broad range of areas of AMS in the hospital setting. These included 7 sets of QIs to address specific infections [CAP, COPD, UTI, Sepsis, *Clostridioides difficile* infection (CDI)], one set of generic QIs to assess antibiotic use in the treatment of all bacterial infections in hospital, 4 sets for specific hospital settings (e.g. ICU, High Dependency Unit (HDU)) and 4 sets of broader QIs to evaluate AMS programmes or hospital antimicrobial prescribing or to compare hospital AMS programmes.

Stakeholder involvement

The most common stakeholders involved in the QI development process were infectious diseases specialists, medical microbiologists, hospital pharmacists and physicians/clinicians. Their expertise was supplemented by various specialist depending on the QIs to be developed (i.e. ICU care involved intensivists, CAP & COPD QIs involved respiratory physicians, UTI QIs- urologists, nephrologists and a gynaecologist). One study reported the participation of patients, payers and policy makers. Five studies reported general details of the stakeholder participants (i.e. multi-disciplinary team or expert group, medical professionals) rather than specific details.

Quality indicators

A total of 229 QIs were extracted from the 16 included studies and the full list is available as supplementary data SD4. QIs were grouped together and duplicates removed where there was conceptual or content overlap and several QIs were extracted from multiple publications. Table 3 contains a description of each unique QI, categorisation of the QI as a structural, process or outcome indicators, classification of QIs by theme within each category, and identification of the studies in which they appeared.

Structural Indicators

55 structural QIs (55/229, 24%) were derived from six studies which aimed to provide a quality assessment of the organisational framework, multi-disciplinary expertise, resources, and supportive activities required to implement an AMS programme. QIs with conceptual or content overlap were grouped together and were classified by themes which were developed and agreed on by all authors. The themes identified were: (1) AMS governance, leadership and accountability [3 indicators, 4 studies], (2) AMS expertise and resources [4 indicators, 3 studies], (3) AMS policies and programmes to improve prescribing [6 indicators, 4 studies], (4) Antimicrobial guidelines [4 indicators, 6 studies], (5) AMS education [1 indicator, 3 studies] and (6) Microbiology laboratory standards, antimicrobial resistance surveillance and feedback [3 indicators, 3 studies].

Process Indicators

172 process indicators (172/229, 75%) were derived from fifteen studies which aimed to assess the general clinical management of all infections, or specific infections, or patient populations. QIs with conceptual or content overlap were grouped together and were classified into four themes: (1) Infection diagnostics [4 indicators, 9 studies], (2) Pharmacy-supported interventions [7 indicators, 8 studies], (3) Elements of good antimicrobial prescribing practice [12 indicators, 12 studies] and (4) Indicators for specific infectious conditions/settings [54 indicators, 10 studies].

Outcome Indicators

Two outcome indicators (2/229, 1%) were identified, recommending the monitoring of clinical outcomes of patients receiving antibiotics and the monitoring of the rate of nosocomial CDI.

Methodological quality

Table 4 presents the results of the critical appraisal of the methodological quality of the 16 QI sets assessed with the AIRE instrument. There was a wide variation in the information and level of detail presented describing the methodological characteristics of the QI sets identified and this was reflected in the AIRE instrument domain scores. Most of the indicator sets achieved a score of 50% or higher indicating a high methodological quality in the first AIRE domain of 'stakeholder involvement'. The 10 studies with a high 'stakeholder involvement' domain score detailed the constituent stakeholders involved in the QI development process which ranged from medical opinion leaders³² to broad multidisciplinary groups.³⁷ Studies considered of lower methodological quality for this domain did not include sufficient information within the publications regarding the relevant stakeholders' involvement in the QI development process. Most studies had a low score for the AIRE item within this domain of 'the indicator has been formally endorsed' with only one study providing this information (QI set endorsed and used by the European Centre for Disease Prevention and Control).³⁰

The 'scientific evidence' domain of the QI development process was well reported and most studies (12) were considered of high methodological quality. Four studies were considered of low quality as

226 they received low or no score due to the absence of information regarding the search methods,
227 evidence base, or the evidence-based appraisal techniques applied to develop the QI sets.

228 The lowest overall methodological quality was seen in the ‘additional evidence, formulation, usage’
229 domain where only 7 studies scored greater than 50%. The AIRE items within this domain which
230 were allocated the lowest scores were ‘a strategy for risk adjustment has been considered and
231 described’, ‘the indicator has sufficient discriminative power’ and ‘specific instructions for
232 presenting and interpreting the indicator results are provided’. Only 8 studies included information
233 regarding the piloting of indicators in practice.

234 Five QI sets were considered to have a high methodological quality in all three AIRE domains^{24 26 27 28}
235²⁹ and only one QI set had scores of less than 50% across all three AIRE domains.³⁸

Discussion

This is the first systematic review to provide an overview and critical appraisal of the methodological quality of QIs for AMS in the hospital setting. A total of 229 QIs were identified from sixteen studies. Process indicators accounted for 75% of the extracted QIs and focused on the clinical management of infections. Structural indicators accounted for 24% of the extracted QIs focussing on the organisational requirements of AMS programmes, and 1% of the extracted QIs assessed outcomes of care. The findings of the critical appraisal of QIs using the AIRE instrument indicate considerable variation in the methodological quality and applicability of the QI sets developed.

Most studies involved a comprehensive QI development process consisting of an appraisal of the evidence-base followed by an expert panel consensus process. There was some variability in the constituents of stakeholders involved in the development of QI sets and several studies did not provide details of the participants of the expert group. The involvement of a diverse range of stakeholders strengthens the results of the consensus process, and enhances the credibility and acceptability of the QIs.³⁹ Patient participation as members of the expert panel of key stakeholders in the QI development is often overlooked⁴⁰ but is of increasing importance.⁴¹ Future studies should ensure the inclusion of a broad range of relevant stakeholders including patients, who all have an interest in the QIs to be developed.

Process indicators for AMS programmes accounted for 75% of the indicators identified. They focused on the general clinical management of infection and antibiotic treatment along with more specific indicators for infectious processes such as sepsis, CAP, COPD and UTIs. Process indicators offer hospitals the ability to assess the core competencies of antimicrobial prescribing⁴² and the opportunity to adapt education and training of prescribers based on the findings. The high proportion of AMS process indicators may be related to the findings that process interventions are considered the most effective AMS strategies to improve antimicrobial prescribing in hospital.³

260 Structural indicators for AMS programmes accounted for 24% of the indicators identified. They
261 focused on the organisational requirements and necessity for a core multi-disciplinary AMS team of
262 infectious diseases specialists, microbiologists and pharmacists providing leadership and expertise to
263 implement and support a multi-faceted AMS programme. AMS programmes are resource intensive
264 which influences the variability in the implementation of hospital AMS programmes worldwide.⁴³
265 Core elements for AMS programme⁴⁴ have been developed which can be adapted depending on the
266 resources available in different countries and hospitals. Structural indicators offer the opportunity to
267 measure the implementation of the proposed core elements and for benchmarking of performance
268 between hospitals, within countries and across jurisdictions and to identify outliers.

269 The low number of outcome indicators identified is reflective of the ongoing challenges of AMS
270 programmes to accurately measure and demonstrate their impact on patient outcomes.^{17 45} Expert
271 panels developing quality measures consider outcome measures important^{17 46} but are often
272 reluctant to include such measures in QI sets due to the need for risk adjustment for confounding
273 factors.⁴⁷ These include changes in the hospital setting such as the patterns of bacterial prevalence,
274 patient demographics, patient case-mix, and infection control interventions and their intensity, all of
275 which can influence AMR and antimicrobial prescribing. Other barriers include concerns that overall
276 clinical outcomes (such as mortality) may be insensitive to changes as a result of interventions such
277 as intravenous to oral switching, and perceived feasibility issues with other outcome measures.⁴⁶ In
278 such situations where there is a difficulty in developing an accurate case-mix adjustment system for
279 outcome indicators then alternative strategies may be more effective at measuring the quality of
280 care.

281 Process and structural indicators can act as direct measures of the quality of healthcare, where a link
282 has been demonstrated between a given process and outcome.⁴⁸ They are relatively easy to
283 measure as the information is accessible from medical records or other hospital sources. They
284 usually assess a clearly defined patient population and thus there is less need for risk adjustment.

285 The availability of such measures and their practicality means they can be used as alternative
286 outcome measures as they are easier to interpret and more sensitive to changes in the quality of
287 care.⁴⁸ The AMS process indicators (use of empiric antimicrobial therapy according to guidelines, de-
288 escalation of therapy, intravenous to oral switching, therapeutic drug monitoring) and structural
289 indicators (use of a list of restricted antibiotics and bedside consultation (especially in
290 *Staphylococcus aureus* bacteraemia)) have demonstrated significant benefit to clinical outcomes,
291 adverse events and costs.⁴⁹ The process measure of documented indications for antimicrobial
292 prescriptions has also shown a positive influence on patient outcomes.⁵⁰ Furthermore a recent study
293 of UK hospitals has evaluated the impact of AMS process and structural indicators (similar to those
294 extracted in this study) on antimicrobial prescribing as an outcome measure and shown promising
295 results.⁴⁵

296 A further possible approach for the development of outcome measures may be to consider using
297 indirect evidence for the success of a process indicator as an outcome. Process indicators such as de-
298 escalation of therapy, or, IV to oral switching, could be used to assess an outcome such as ‘not
299 showing harm’ where such indicators could decrease the likelihood of catheter-related
300 infections/events without demonstrating an impact on more traditional outcomes such as mortality
301 or AMR rates.⁴⁹

302 The development of future QIs must address the lack of outcome indicators currently available while
303 acknowledging the difficulties in their development such as risk adjustment and case-mix, along with
304 the multitude of other factors which can influence AMR. The potential use of AMS process and
305 structural indicators with a direct link to outcomes should also be explored further as surrogate AMS
306 outcome measure.⁴⁵

307 The methodological requirements for the development of QIs are well established.^{9,12} Most studies
308 concentrated on the development of the QIs and were considered of high methodological quality in
309 the ‘stakeholder involvement’ and ‘scientific evidence’ domains. However, studies scored poorly in

the 'additional evidence, formulation, usage' domain due to limited reporting of information about validation and piloting of the QIs in practice or testing of the clinimetric characteristics. Such practice testing prior to wider usage of QIs is essential⁴⁰ as the validation and clinimetric testing of QIs is important to demonstrate the applicability and implementability of QI sets in practice, in different settings and to demonstrate the robustness of the indicators. The studies which were considered of the highest methodological quality scored well in all three AIRE domains and recognised the need to test indicators in the setting where they are intended for use.^{24 26-29}

Several studies, which were considered of high methodological quality in the first two AIRE domains had low scores in the third domain.^{23 30 31 36 37} Some studies acknowledged the need for piloting and clinimetric testing of their QIs prior to use on a wider scale.^{27 30 31 35 37} The QIs from two studies^{27 37} have undergone subsequent clinimetric testing.^{51 52} This resulted in one QI set reducing the 11 initial QIs to 7, based on applicability⁵¹ and of 33 QIs assessed reduced to 18 process indicators considered suitable to identify processes with a greater need for improvement within an AMS programme.⁵² This supports the findings seen in other studies which have shown that 10-20% of developed QIs are not measurable in practice.⁵³ The implementability, applicability and feasibility testing of indicator measurements are important considerations and should be conducted as part of the development process but also in new settings where the QIs are to be potentially applied. Potential users need to know if they will be able to retrieve the data to assess the QI from sources such as medical records and this may vary between countries and sometimes within clinical settings.^{28 30 51}

Point prevalence surveys are one of the most frequently used methods to assess the quality of antimicrobial prescribing in the hospital setting⁵⁴ and have been used to test QIs sets.^{51 52} They are a particularly useful method of assessing the impact of process indicators on patient care and outcomes⁵⁵ in practice so future QI development studies should consider if new process QI sets can be incorporated and applied in point prevalence surveys.

Strengths and limitations of this study

This is the first systematic review of the QIs for AMS programmes which has included a critical appraisal of the methodological quality of the QI sets, a strength of this study.

The selection of articles, data extraction and quality assessment with the AIRE assessment tool was conducted by two reviewers independently and showed good inter-rater reliability which increases the overall reliability of the results. This review included QIs assessing specific infectious conditions as well as broader QIs of AMS programmes so provides a comprehensive overview of AMS programme QIs.

We may have missed some QI sets which have not been published in an article or report. However, it is unlikely that validated and reliable QI sets for AMS have not been published in peer-reviewed literature.

The AIRE instrument used in this study to assess the methodological quality of studies mainly focusses on the QI development process and scores are allocated based on the information contained within the published article. Unfortunately, the process of developing QIs was not always reported in detail in studies and this resulted in some studies being assigned lower scores for these criteria. As a result of this limitation the methodological quality of the QIs identified in this article may have been underestimated by using the AIRE instrument. There were, however, some studies which acknowledged the need to conduct piloting and clinimetric testing of their indicators so the low scores in these situations were accurate. A further limitation of this study was that we relied solely on the information contained within the published article.

Conclusions

This review provides an overview and critical appraisal of the methodological quality of QIs of AMS programmes. The study highlights the continuing need for transparent, valid and feasible QIs. Studies to date have focused on process and structural indicators with few outcome indicators developed, a major deficiency in this area. Future research should focus on the development of outcome indicators or the use of process or structural indicators linked to outcomes to assess AMS.

360 Testing of the QIs in practice should be an essential element of the QI development process and
361 should be included in the QI development study or as planned validation work.

362 **Acknowledgements**

363 The authors would like to thank Joe Murphy and Breeda Herlihy, MUH medical library for their
364 assistance in the development of the literature searches.

365 **Funding**

366 The study was supported by internal funding.

367

368 **Transparency declarations**

369 Nothing to declare

References

1. O'Neill J. Antimicrobial resistance: tackling a crisis for the health and wealth of nations. *London (UK) HM Government*: 2014 https://amr-review.org/sites/default/files/AMR%20Review%20Paper%20-%20Tackling%20a%20crisis%20for%20the%20health%20and%20wealth%20of%20nations_1.pdf
2. World Health Organisation. Global action plan on antimicrobial resistance 2015. https://apps.who.int/iris/bitstream/handle/10665/193736/9789241509763_eng.pdf?sequence=1
3. Davey P, Marwick CA, Scott CL, *et al*. Interventions to improve antibiotic prescribing practices for hospital inpatients. *Cochrane Database Syst Rev* 2017;**2**:CD003543.
4. File TM Jr, Srinivasan A, Bartlett JG. Antimicrobial stewardship: importance for patient and public health. *Clin Infect Dis* 2014;**59** Suppl 3:S93-6.
5. SARI Hospital Antimicrobial Stewardship Working Group. Guidelines for Antimicrobial Stewardship in Hospitals in Ireland. https://www.hpsc.ie/az/microbiologyantimicrobialresistance/infectioncontrolandhai/guidelines/File_4116.en.pdf
6. Dellit TH, Owens RC, McGowan JE Jr, *et al*. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. *Clin Infect Dis* 2007;**44**:159-77.
7. Lawrence M, Olesen F. Indicators of Quality in Health Care. *European Journal of General Practice* 1997;**3**:103-08.
8. Donabedian A. The quality of care. How can it be assessed? *JAMA* 1988;**260**:1743-8.
9. Rubin HR, Pronovost P, Diette GB. From a process of care to a measure: the development and testing of a quality indicator. *International Journal for Quality in Healthcare* 2001;**13**:489-96
10. Mainz J. Defining and classifying clinical indicators for quality improvement. *International Journal for Quality in Healthcare* 2003;**15**:523-30.

- 395 11. Brook RH, Chassin MR, Fink A, *et al.* A method for the detailed assessment of the
396 appropriateness of medical technologies. *Int J Technol Assess Health Care* 1986;**2**:53-63.
- 397 12. Campbell SM, Braspenning J, Hutchinson A, *et al.* Research methods used in developing and
398 applying quality indicators in primary care. *BMJ* 2003;**326**:816-9.
- 399 13. McGlynn EA, Asch SM. Developing a clinical performance measure. *Am J Prev Med* 1998;**14**(3
400 Suppl):14-21.
- 401 14. Johannsson B, Beekmann SE, Srinivasan A, *et al.* Improving antimicrobial stewardship: the
402 evolution of programmatic strategies and barriers. *Infect Control Hosp Epidemiol* 2011;**32**:367-74.
- 403 15. Morris AM, Brener S, Dresser L, *et al.* Use of a Structured Panel Process to Define Quality Metrics
404 for Antimicrobial Stewardship Programs. *Infection Control and Hospital Epidemiology* 2012;**33**:500-
405 06.
- 406 16. Nathwani D, Varghese D, Stephens J, *et al.* Value of hospital antimicrobial stewardship programs
407 [ASPs]: a systematic review. *Antimicrobial Resistance & Infection Control* 2019;**8**:35.
- 408 17. Bumpass JB, McDanel PM, DePestel DD, *et al.* Outcomes and metrics for antimicrobial
409 stewardship: survey of physicians and pharmacists. *Clin Infect Dis* 2014;**59** Suppl 3:S108-11.
- 410 18. PRISMA. Prisma Transparent Reporting of Systematic Reviews and Meta-analysis.
411 <http://www.prisma-statement.org>
- 412 19. Akpan MR, Ahmad R, Shebl NA, *et al.* A Review of Quality Measures for Assessing the Impact of
413 Antimicrobial Stewardship Programs in Hospitals. *Antibiotics (Basel)* 2016;**5**:5.
- 414 20. Kallen MC, Prins JM. A Systematic Review of Quality Indicators for Appropriate Antibiotic Use in
415 Hospitalized Adult Patients. *Infect Dis Rep* 2017;**9**:6821-21.
- 416 21. de Koning J SA, Klazinga NS. The Appraisal of Indicators through Research and Evaluation (AIRE)
417 instrument. *Amsterdam:Academic Medical Center* 2006
- 418 22. de Koning J. Development and validation of a measurement instrument for appraising indicator
419 quality: appraisal of indicators through research and evaluation (AIRE) instrument. *Kongress Medizin*

und Gesellschaft 17-21092007; Augsburg Düsseldorf: German Medical Science GMS Publishing House;2007

23. Berenholtz SM, Pronovost PJ, Ngo K, *et al.* Developing quality measures for sepsis care in the ICU. *Jt Comm J Qual Patient Saf* 2007;**33**:559-68.

24. Buyle FM, Metz-Gercek S, Mechtler R, *et al.* Development and validation of potential structure indicators for evaluating antimicrobial stewardship programmes in European hospitals. *European Journal of Clinical Microbiology & Infectious Diseases* 2013;**32**:1161-70.

25. Coll A, Kinnear M, Kinnear A. Design of antimicrobial stewardship care bundles on the high dependency unit. *International Journal of Clinical Pharmacy* 2012;**34**:845-54.

26. Farida H, Rondags A, Gasem MH, *et al.* Development of quality indicators to evaluate antibiotic treatment of patients with community-acquired pneumonia in Indonesia. *Tropical Medicine & International Health* 2015;**20**:501-09.

27. Thern J, De With K, Strauss R, *et al.* Selection of hospital antimicrobial prescribing quality indicators: A consensus among German antibiotic stewardship (ABS) networkers. *Infection* 2014;**42**:351-62.

28. Hermanides HS, Hulscher M, Schouten JA, *et al.* Development of quality indicators for the antibiotic treatment of complicated urinary tract infections: A first step to measure and improve care. *Clinical Infectious Diseases* 2008;**46**:703-11.

29. Kallen MC, Roos-Blom MJ, Dongelmans DA, *et al.* Development of actionable quality indicators and an action implementation toolbox for appropriate antibiotic use at intensive care units: A modified-RAND Delphi study. *Plos One* 2018;**13**:e0207991.

30. Monnier AA, Schouten J, Le Maréchal M, *et al.* Quality indicators for responsible antibiotic use in the inpatient setting: A systematic review followed by an international multidisciplinary consensus procedure. *Journal of Antimicrobial Chemotherapy* 2018;**73**:vi30-vi39.

444 31. Pollack LA, Plachouras D, Sinkowitz-Cochran R, *et al.* A Concise Set of Structure and Process
445 Indicators to Assess and Compare Antimicrobial Stewardship Programs Among EU and US Hospitals:
446 Results From a Multinational Expert Panel. *Infect Control Hosp Epidemiol* 2016;**37**:1201-11.

447 32. Schouten JA, Hulscher ME, Wollersheim H, *et al.* Quality of antibiotic use for lower respiratory
448 tract infections at hospitals: (how) can we measure it? *Clin Infect Dis* 2005;**41**:450-60.

449 33. Schouten J, De Angelis G, Sprong T, *et al.* Evidence-based recommendations to increase the
450 appropriate usage of antibiotics in ICU patients: A 5-day bundle. *Intensive Care Medicine*
451 2012;**38**:S237. Abstract 0878

452 34. Sneddon J, Patton A, Nathwani D, *et al.* Improving hospital antimicrobial prescribing using quality
453 indicators. *Clinical Microbiology and Infection* 2012;**18**:107. Abstract O654

454 35. Ten Oever J, Jansen JL, Van Der Vaart TW, *et al.* Development of quality indicators for the
455 management of *Staphylococcus aureus* bacteraemia. *Journal of Antimicrobial Chemotherapy*
456 2019;**74**:3344-51.

457 36. van den Bosch CMA, Hulscher M, Natsch S, *et al.* Development of quality indicators for
458 antimicrobial treatment in adults with sepsis. *Bmc Infectious Diseases* 2014;**14**:345

459 37. Van Den Bosch CMA, Geerlings SE, Natsch S, *et al.* Quality indicators to measure appropriate
460 antibiotic use in hospitalized adults. *Clinical Infectious Diseases* 2015;**60**:281-91.

461 38. Vera P, Palomar M, Alvarez-Lerma F. Quality indicators on the use of antimicrobials in critically ill
462 patients. *Med Intensiva* 2014;**38**:567-74.

463 39. Boulkedid R, Abdoul H, Loustau M, *et al.* Using and reporting the Delphi method for selecting
464 healthcare quality indicators: a systematic review. *PLoS One* 2011;**6**:e20476.

465 40. Kötter T, Blozik E, Scherer M. Methods for the guideline-based development of quality
466 indicators--a systematic review. *Implementation Science* 2012;**7**:21.

467 41. Luxford K. What does the patient know about quality? *International Journal for Quality in Health*
468 *Care* 2012;**24**:439-40.

469 42. Dyar OJ, Beović B, Pulcini C, *et al.* ESCMID generic competencies in antimicrobial prescribing and
470 stewardship: towards a European consensus. *Clinical Microbiology and Infection* 2019;**25**:13-19.

471 43. Cox JA, Vlieghe E, Mendelson M, *et al.* Antibiotic stewardship in low- and middle-income
472 countries: the same but different? *Clin Microbiol Infect* 2017;**23**:812-18.

473 44. Pulcini C, Binda F, Lamkang AS, *et al.* Developing core elements and checklist items for global
474 hospital antimicrobial stewardship programmes: a consensus approach. *Clinical Microbiology and*
475 *Infection* 2019;**25**:20-25.

476 45. Scobie A, Budd EL, Harris RJ, *et al.* Antimicrobial stewardship: an evaluation of structure and
477 process and their association with antimicrobial prescribing in NHS hospitals in England. *Journal of*
478 *Antimicrobial Chemotherapy* 2019;**74**:1143-52.

479 46. Moehring RW, Anderson DJ, Cochran RL, *et al.* Expert Consensus on Metrics to Assess the Impact
480 of Patient-Level Antimicrobial Stewardship Interventions in Acute-Care Settings. *Clinical Infectious*
481 *Diseases* 2017;**64**:377-83.

482 47. McGowan JE. Antimicrobial stewardship--the state of the art in 2011: focus on outcome and
483 methods. *Infect Control Hosp Epidemiol* 2012;**33**:331-7.

484 48. Mant J. Process versus outcome indicators in the assessment of quality of health care.
485 *International journal for quality in health care : Journal of the International Society for Quality in*
486 *Health Care* 2001;**13**:475-80.

487 49. Schuts EC, Hulscher M, Mouton JW, *et al.* Current evidence on hospital antimicrobial stewardship
488 objectives: a systematic review and meta-analysis. *Lancet Infect Dis* 2016;**16**:847-56.

489 50. Wagner JL, Carreno JJ, Kenney RM, *et al.* Antimicrobial Stewardship Metrics that Matter.
490 *Infectious Diseases in Clinical Practice* 2020;**28**:89-93.

491 51. van den Bosch CMA, Hulscher MEJL, Natsch S, *et al.* Applicability of generic quality indicators for
492 appropriate antibiotic use in daily hospital practice: a cross-sectional point-prevalence multicenter
493 study. *Clinical Microbiology and Infection* 2016;**22**:888.e1-88.e9.

494 52. Först G, Kern WV, Weber N, *et al.* Clinimetric properties and suitability of selected quality
495 indicators for assessing antibiotic use in hospitalized adults: a multicentre point prevalence study in
496 24 hospitals in Germany. *Journal of Antimicrobial Chemotherapy* 2019;**74**:3596-602.

497 53. Wollersheim H, Hermens R, Hulscher M, *et al.* Clinical indicators: development and applications.
498 *Netherlands Journal of Medicine* 2007;**65**:15-22.

499 54. Plachouras D, Kärki T, Hansen S, *et al.* Antimicrobial use in European acute care hospitals: results
500 from the second point prevalence survey (PPS) of healthcare-associated infections and antimicrobial
501 use, 2016 to 2017. *Eurosurveillance* 2018;**23**:1800393.

502 55. Zarb P, Amadeo B, Muller A, *et al.* Identification of targets for quality improvement in
503 antimicrobial prescribing: the web-based ESAC Point Prevalence Survey 2009. *Journal of*
504 *Antimicrobial Chemotherapy* 2011;**66**:443-49.

| AIRE domain | AIRE items |
|---|---|
| Stakeholder involvement | 1. The group developing the indicator includes individuals from relevant professional groups |
| | 2. Considering the purpose of the indicator, all relevant stakeholders have been involved at some stage of the development process |
| | 3. The indicator has been formally endorsed |
| Scientific evidence | 4. Systematic methods were used to search for scientific evidence |
| | 5. The indicator is based on recommendations from an evidence-based guideline or studies published in peer-reviewed scientific journals |
| | 6. The supporting evidence has been critically appraised |
| Additional evidence, formulation, usage | 7. The numerator and denominator are described in detail |
| | 8. The target patient population of the indicator is defined clearly |
| | 9. A strategy for risk adjustment has been considered and described ('case-mix adjustment') |
| | 10. The indicator measures what it is intended to measure (validity) |
| | 11. The indicator measures accurately and consistently (reliability) |
| | 12. The indicator has sufficient discriminative power |
| | 13. The indicator has been piloted in practice |
| | 14. The efforts needed for data collection have been considered |
| | 15. Specific instructions for presenting and interpreting the indicator results are provided |

| Author, year, location | Aim/focus | Study description | Stakeholder involvement | Number of AMS indicators per type |
|---------------------------------------|--|--|--|-----------------------------------|
| Berenholtz ²³ 2007, USA | Sepsis care | Interdisciplinary panel literature review and a modified Delphi procedure with a multi-disciplinary expert panel from multiple hospitals | Physicians, nurses and pharmacist with expertise in sepsis, critical care and infectious diseases (ID), and experts in developing quality measures | Process:6 Structural:0 |
| Buyle ²⁴ 2013, Europe | Structural indicators to evaluate AMS programmes | Literature review and consensus process with a 13-member multi-disciplinary panel from multiple (4) countries | 5 ID specialists, 2 clinical microbiologists, 3 hospital pharmacists, 3 quality of health-care experts | Process:0 Structural:10 |
| Coll ²⁵ 2012, UK | AMS in a high dependency unit | Multi-disciplinary team agreement, reference to the evidence base, national strategy and local policy | Multi-disciplinary team | Process: 30 Structural:0 |
| Farida ²⁶ 2015, Indonesia | Development of QIs for the antimicrobial management of CAP | QI development based on a previous study and guideline review followed by a 2 step Delphi procedure with an 18-member national multi-disciplinary expert panel | 10 internists, 3 internist-pulmonologists, 2 pharmacists, 3 clinical microbiologists | Process:6 Structural:0 |
| Thern ²⁷ 2014, Europe | Hospital antimicrobial prescribing quality indicators | Literature review and RAND/UCLA appropriateness consensus with a multi-disciplinary expert panel from multiple hospitals | Clinicians, hospital pharmacists, microbiologists, infection control doctors | Process:21 Structural:21 |
| Hermanides ²⁸ 2008, Europe | QIs for the antibiotic treatment of complicated UTIs | Evidence based guidelines used in a 3-step modified Delphi approach with a 13-member multi-disciplinary expert panel from multiple hospitals | 2 Medical microbiologists, 4 ID specialists, 2 hospital pharmacists, 2 urologists, 2 nephrologists, 1 gynaecologist | Process:13 Structural:0 |

| | | | | |
|--|--|---|--|---|
| Kallen ²⁹ 2018, Europe | QIs for appropriate antibiotic use in the ICU | Literature review and four round modified RAND Delphi procedure with a 15-member multi-disciplinary expert panel of Dutch experts | 3 anaesthesiologists-intensivists, 3 internist-intensivists, 1 intensivist-infectious diseases physician, 3 internists-ID physicians, 2 clinical microbiologists, 3 clinical pharmacists | Process:3 Structural:1 (1 quality metric) |
| Monnier ³⁰ 2018, Europe | QIs for responsible inpatient antibiotic use | Systematic literature review and a four step RAND modified Delphi method with a 25-member international multi-disciplinary expert panel | Medical community (15) public health and patients (12); antibiotic R&D (14); and payers, policymakers, governments and regulators (11). | Process:35 Structural:14 Outcome:2 |
| Pollack ³¹ 2016, USA & Europe | QIs to assess and compare AMS programmes among US and EU hospitals | Literature review followed by Modified Delphi process using RAND/UCLA appropriateness method with a 20-member multi-disciplinary multinational expert panel | Clinical medicine, pharmacy, public health | Process:10 Structural:7 |
| Schouten ³² 2005, Europe | Measurement of the quality of antibiotic use in CAP & COPD | Literature and guideline review and a four step modified Delphi procedure with 11-member medical opinion leader expert panel from multiple hospitals | Medical microbiology, ID, respiratory medicine, quality of care medicine | Process:15 Structural:0 |
| Schouten ³³ 2012, Europe | QI bundle for ICU antimicrobial use | Literature search followed by a 2 round RAND modified Delphi method with 11 member multi-disciplinary expert panel from 6 EU countries | 11 member multi-disciplinary expert panel | Process: 6 Structural:0 |
| Sneddon ³⁴ 2012, UK | QIs to support a 50% reduction in CDI and improve prescribing practice | Development and implementation of QIs based on national CDI target reduction | Scottish Antimicrobial Prescribing Group | Process:2 Structural:0 |

| | | | | |
|--|---|---|--|----------------------------|
| Ten Oever ³⁵ 2019, Europe | QIs for the management of <i>Staphylococcus Aureus</i> bacteraemia | Systematic literature review followed by a RAND modified Delphi procedure with an international expert panel of medical professionals | Medical professionals (MD) | Process:11 Structural:0 |
| Van den Bosch ³⁶ 2014, Europe | QIs for antimicrobial treatment in adults with sepsis | QIs from national sepsis guidelines followed by a RAND modified Delphi consensus with a 14-member multi-disciplinary expert panel from multiple hospitals | 4 ID physicians, 2 medical microbiologists, 2 hospital pharmacists, 3 intensive care specialists, two haematologists, 1 general surgeon | Process:5 Structural:0 |
| Van den Bosch ³⁷ 2015, Europe | QIs to measure appropriate antimicrobial use in hospitalised adults | Literature review followed by a RAND modified Delphi consensus with a 17-member international multi-disciplinary expert panel | 5 medical microbiologists, 4 ID specialists, 2 clinical hospital pharmacists, 2 general surgeons, 2 pulmonologists, and 2 gynaecologists | Process: 9 Structural:2 |
| Vera ³⁸ 2014, Europe | QIs for antimicrobial use in critically ill (ICU) patients | Selection of QIs proposed by Spanish working group of Infectious Diseases followed by validity and reliability confirmation and review of supporting evidence | Spanish working group of Infectious Diseases | Process:10 Structural:0 |

Figure 1: PRISMA flow diagram of literature search




Table 3. Quality indicators

| Indicator | Source (s), Reference(s) | Description of the indicator |
|--|---|--|
| Structural Indicators by theme | | |
| AMS governance, leadership and accountability | <p>Buyle 2013, Thern 2014, Monnier 2018, Pollack 2016</p> <p>Buyle 2013, Thern 2014</p> <p>Thern 2014, Monnier 2018, Pollack 2016</p> | <p>Establish a multi-disciplinary AMS committee that meets regularly.</p> <p>AMS representation and membership of the hospitals drugs and therapeutic committee.</p> <p>Strategic report submitted to D&T and hospital management including quantitative objectives and selected performance indicators.</p> |
| AMS multi-disciplinary expertise and resources | <p>Buyle 2013, Pollack 2016</p> <p>Monnier 2018</p> <p>Pollack 2016</p> <p>Pollack 2016</p> | <p>Dedicated physician and pharmacist resources to provide AMS advice (and AMS leadership).</p> <p>Antibiotics from the antibiotic formulary should not be out of stock at the health care facility.</p> <p>Salary support for dedicated time for antimicrobial stewardship activities.</p> <p>Information technology capability to support the needs of the AMS activities.</p> |
| AMS policies and programmes to improve antimicrobial prescribing | <p>Buyle 2013, Monnier 2018, Pollack 2016</p> <p>Buyle 2013, Thern 2014, Monnier 2018, Pollack 2016</p> <p>Thern 2014, Monnier 2018, Pollack 2016</p> <p>Buyle 2013, Thern 2014, Pollack 2016</p> <p>Thern 2014</p> <p>Monnier 2018</p> | <p>AMS programme should be in place (including reports, objectives, performance indicators).</p> <p>Audit and feedback to prescribers of antimicrobial consumption and prescribing practices (including indications, surgical prophylaxis choice and duration).</p> <p>Restricted antimicrobials requiring approval.</p> <p>Regular AMS ward rounds and availability of expert consultation advice.</p> <p>Written recommendation for parenteral-to-oral switch antimicrobial therapy.</p> <p>Prophylactic antibiotics should be added to a pre-operative checklist.</p> |

| | | |
|---|--|---|
| | Pollack 2016 | Policy that requires prescribers to document an indication in the medical record or during order entry for all antimicrobial prescriptions. |
| Antimicrobial guidelines | <p>Buyle 2013, Thern 2014, Monnier 2018, Pollack 2016, Van der Bosch 2014, Van der Bosch 2015</p> <p>Buyle 2013, Thern 2014 Buyle 2013, Thern 2014, Monnier 2018 Thern 2014</p> | <p>Antimicrobial guidelines (correspond to national guideline but should be adapted based on local resistance patterns and updated biannually).</p> <p>Surgical antimicrobial policy.</p> <p>Antimicrobial formulary.</p> <p>Electronically available guideline/ decision making aids.</p> |
| AMS education | Buyle 2013, Thern 2014, Monnier 2018 | AMS prescriber education provided. |
| Microbiology laboratory standards, antimicrobial resistance surveillance and feedback | <p>Thern 2014</p> <p>Thern 2014, Monnier 2018</p> <p>Thern 2014, Monnier 2018, Pollack 2016</p> | <p>Written in-house preanalytical requirements for microbiologic samples (including rejection criteria).</p> <p>Use of selected antibiograms (adapted according to local guidelines).</p> <p>Reporting of AMR resistance rates, <i>C.difficile</i> incidence, nosocomial sepsis/bacteraemia rates for clinical isolates available annually (and for specific services).</p> |
| Process indicators by theme | | |
| Infection diagnostics | <p>Coll 2012, Thern 2014, Hermanides 2008, Kallen 2018, Monnier 2018, Schouten 2005, Schouten 2012, Van der Bosch 2014, Van der Bosch 2015, Farida 2015</p> <p>Coll 2012, Monnier 2018</p> <p>Monnier 2018</p> <p>Monnier 2018</p> | <p>Before starting antimicrobial therapy, at least two sets of blood cultures and specimens for culture from suspected sites of infection should be taken (sputum, urine, etc).</p> <p>The results of bacteriological sensitivity(s) is documented.</p> <p>Microbiological investigations should be performed according to guidelines.</p> <p>Clinical and laboratory sepsis parameters should be documented in the medical records when prescribing antibiotics.</p> |
| Pharmacy-supported interventions | <p>Coll 2012, Monnier 2018</p> <p>Coll 2012, Monnier 2018</p> <p>Monnier 2018</p> | <p>Allergy status and documentation.</p> <p>Interaction management with concurrent medication.</p> <p>Contra-indications should be taken into account when prescribing antibiotics.</p> |

| | | |
|---|---|--|
| | <p>Coll 2012, Kallen 2018, Monnier 2018, Ten Oever 2019, Van der Bosch 2015</p> <p>Coll 2012, Thern 2014, Hermanides 2008, Monnier 2018, Schouten 2005, Ten Oever 2019, Van der Bosch 2015</p> <p>Thern 2014</p> <p>Monnier 2018</p> | <p>Therapeutic drug monitoring of vancomycin and gentamicin is conducted correctly and documented. Monitoring and adjustment of antimicrobial treatment for renal impairment.</p> <p>Oral administration of drugs with high bioavailability. The dosage regimen of antibiotics with an increased risk of toxicity (such as vancomycin or gentamicin) should be managed according to guidelines.</p> |
| Important elements of good antimicrobial prescribing practice | <p>Coll 2012, Thern 2014, Hermanides 2008, Monnier 2018, Schouten 2005, Schouten 2012, Ten Oever 2019, Van der Bosch 2014, Van der Bosch 2015</p> <p>Coll 2012, Hermanides 2008, Schouten 2012, Sneddon 2012</p> <p>Farida 2015, Monnier 2018, Schouten 2005, Van der Bosch 2015</p> <p>Coll 2012, Monnier 2018, Schouten 2012</p> <p>Coll 2012, Hermanides 2008, Monnier 2018, Schouten 2005, Schouten 2012, Van der Bosch 2014, Van der Bosch 2015</p> <p>Monnier 2018, Schouten 2005, Farida 2015</p> <p>Monnier 2018, Van der Bosch 2015</p> <p>Coll 2012, Hermanides 2008, Monnier 2018, Schouten 2012</p> <p>Monnier 2018, Van der Bosch 2015</p> <p>Monnier 2018</p> | <p>Empiric systemic antimicrobial therapy should be compliant/prescribed according to local policy guidelines (choice, route, dosage).</p> <p>Documentation of an antimicrobial plan including indication for prescribing, intended duration of treatment.</p> <p>Prompt administration of antimicrobial within 4 hours of presentation.</p> <p>Antimicrobial treatment is reviewed according to clinical response and/or sensitivities.</p> <p>Empiric systemic antimicrobial therapy should be changed to pathogen-directed therapy if culture results become available.</p> <p>Prompt switching from intravenous route of administration to oral when clinically appropriate.</p> <p>Duration of antibiotic therapy should be compliant with guidelines.</p> <p>Antibiotic therapy should be discontinued based on the lack of clinical evidence of infection.</p> <p>Antimicrobial treatment is discontinued on completion of the documented course.</p> <p>Antibiotic prescriptions that deviate from guidelines should be justified.</p> |

| | | |
|--|--|---|
| | Van der Bosch 2015 | Prescribed antibiotics should actually be administered to the patients. The maximum duration of empirical systemic antibiotic treatment should be seven days. |
| Specific infectious conditions/settings | | |
| Surgical antimicrobial prophylaxis (SAP) | Thern 2014, Monnier 2018, Sneddon 2012 | SAP (drug and dosage): administered according to local guidelines. SAP administered within 1 hour before incision. SAP discontinued with 1 day (24 hours). |
| Community acquired pneumonia | Schouten 2005, Farida 2015 | Prescribe antibiotic therapy for exacerbations only when indicated. Optimal duration of antibiotic therapy from 5-7 days. |
| Chronic obstructive pulmonary disease | Schouten 2005 | Prescribe antibiotic therapy for exacerbations only when indicated. Optimal duration of antibiotic therapy from 5-7 days. |
| Hospital acquired pneumonia | Thern 2014 | Duration of therapy no longer than 10 days. |
| Urinary tract infections | Thern 2014 Hermanides 2008 | Documentation of positive urine culture. Duration of pyelonephritis therapy not longer than 10 days (patients on general ward). Oral antimicrobial drugs initiated not later than day 5 (pyelonephritis, patients on normal wards only). No antimicrobials for asymptomatic, catheter-associated bacteriuria. Selective use of fluoroquinolones (only as oral or in beta-lactam allergy/anaphylaxis). Duration of treatment for at least 10 days (in accordance with national guideline). Prescription of treatment for men in accordance with national guidelines. Start iv antibiotics in pregnant women with pyelonephritis. Do not prescribe antibiotic prophylaxis to patients with a urinary catheter in place. |

| | | |
|---|--|--|
| | | <p>Intravenous-to-oral switch should not be performed in complicated SAB after 48–72 h.</p> <p>Other management aspects:</p> <p>Infectious disease specialist consultation should be performed in patients with SAB.</p> <p>SAB should be documented in the medical discharge summary.</p> |
| Multi drug resistant infection management | Thern 2014 | Infection and/or colonization by multidrug- resistant (MDR) organisms explicitly listed on discharge summary. |
| Sepsis | <p>Monnier 2018, Van der Bosch 2014</p> <p>Berenholtz 2007</p> | <p>Antimicrobial therapy in adult patients with sepsis should be started intravenously.</p> <p>Antimicrobial therapy should be started as soon as possible, preferably within the first hour in adult patients with severe sepsis and septic shock.</p> <p>Vancomycin prescribing-% of sepsis patients with unidentified organism received vancomycin within 24 hours of identification.</p> <p>Median time to vancomycin following sepsis diagnosis.</p> <p>% of patients with sepsis and an unidentified organism who received a recommended broad spectrum antibiotic within 24 hours of sepsis diagnosis.</p> <p>Median time to broad spectrum antibiotic initiation following sepsis diagnosis.</p> <p>% of patients with sepsis who had 2 sets of blood cultures collected within 24 hours following sepsis identification.</p> <p>% of patients with sepsis and an organism other than MRSA or MRSE (metacillin-resistant staphylococcus epidermis) who had vancomycin discontinued within 96 hours of diagnosis.</p> |
| ICU | Kallen 2018 | Perform surveillance cultures if selective digestive or oropharyngeal decontamination is applied at the ICU . |

| | | |
|--|-----------|---|
| | Vera 2014 | <p>Biannual face-to-face meetings between ICU and microbiology staff in which local resistance rates are discussed.</p> <p>Antimicrobial use in the intensive care unit Formula: Total number of days of use of antimicrobial agent / Total number of days of ICU patients × 100.</p> <p>Non-empirical antimicrobial use Formula: Total antimicrobials used to treat infections in a directed manner / Total of antimicrobials used to treat infections × 100.</p> <p>Changes in antimicrobials used as treatment Formula: Total number of antimicrobials changed to another antimicrobial / Total of antimicrobials used to treat infections × 100.</p> <p>Days without antimicrobial use in ICU Formula: Total number of ICU days without antimicrobials / Total number of days of ICU patients × 100.</p> <p>Days free of antimicrobials in patients on antimicrobial treatment Formula: Number of days free of antimicrobials in patients on antimicrobial treatment / Total days in ICU of patients on antimicrobial treatment × 100 .</p> <p>Number of days of antimicrobials for surgical prophylaxis Formula: Number of days of use of antimicrobials for surgical prophylaxis / Total number of patients with surgical prophylaxis treatment × 100.</p> <p>Inappropriate empirical antimicrobial treatment Formula: Total number of inappropriate empirical antimicrobials / Total number of empirical antimicrobials used to treat infections × 100.</p> <p>Empirical antimicrobials changed because they are inadequate Formula: Number of empirical</p> |
|--|-----------|---|

| | | |
|------------------------------------|--------------|--|
| | | <p>antimicrobials changed because they are inadequate Total number of empirical antimicrobials used to treat infections $\times 100$.</p> <p>Empirical antimicrobial changed for de-escalation Formula: Number of empirical antimicrobials changed by adjustment or de-escalation / Total number of empirical antimicrobials used to treat infections $\times 100$.</p> <p>Patients with severe sepsis/septic shock treated with antimicrobials in the first three hours Formula: Number of patients with severe sepsis/septic shock, treated with antimicrobials in the first 3 hours / Total number of patients with severe sepsis/septic shock $\times 100$.</p> |
| Outcome indicators by theme | | |
| Clinical outcome | Monnier 2018 | <p>Clinical outcomes of patients receiving antibiotics should be monitored at the health care facility.</p> <p>Rates of nosocomial <i>Clostridioides difficile</i> should be monitored at the health care facility.</p> |

Table 4. Critical appraisal of the publications using the AIRE instrument

[illegible]

| | | | | | | | | | | | | | | | | | | |
|-------------------------------------|-----|-----|-----|------------|-----|-----|-----|-------------|-----|-----|-----|-----|-----|-----|-----|-----|-----|------------|
| Pollack ³¹ 2016 | 4,4 | 4,4 | 1,1 | 67% | 4,4 | 4,4 | 2,2 | 78% | 3,4 | 4,4 | 1,1 | 1,1 | 1,1 | 1,1 | 1,1 | 3,3 | 1,1 | 28% |
| Schouten ³² 2005 | 2,2 | 3,3 | 1,1 | 39% | 4,4 | 4,4 | 4,3 | 94% | 2,2 | 4,4 | 4,4 | 4,4 | 4,4 | 4,4 | 4,4 | 4,4 | 1,1 | 83% |
| Schouten ³³ 2012 | 2,2 | 1,1 | 1,1 | 11% | 1,1 | 2,2 | 1,1 | 11% | 2,2 | 4,4 | 1,1 | 3,3 | 1,1 | 1,1 | 4,4 | 4,3 | 1,1 | 43% |
| Sneddon ³⁴ 2012 | 2,2 | 1,1 | 1,1 | 11% | 1,1 | 1,1 | 1,1 | 0% | 4,3 | 4,4 | 1,1 | 4,1 | 4,4 | 1,1 | 4,4 | 2,2 | 4,4 | 61% |
| Ten Oever ³⁵ 2019 | 3,3 | 3,3 | 1,1 | 44% | 4,4 | 4,4 | 4,4 | 100% | 2,2 | 4,4 | 1,1 | 1,1 | 1,1 | 1,1 | 1,1 | 1,1 | 1,1 | 15% |
| Van den Bosch ³⁶ 2014 | 4,3 | 4,4 | 1,1 | 61% | 1,1 | 4,3 | 3,3 | 50% | 4,4 | 4,4 | 1,1 | 1,1 | 1,1 | 1,1 | 1,1 | 1,1 | 1,1 | 22% |
| Van den Bosch ³⁷ 2015 | 4,3 | 4,4 | 1,1 | 61% | 3,4 | 4,4 | 4,4 | 94% | 4,4 | 4,4 | 1,1 | 1,1 | 1,1 | 1,1 | 1,1 | 1,1 | 1,1 | 22% |
| Vera ³⁸ 2014 | 1,1 | 1,1 | 1,1 | 0% | 1,1 | 1,1 | 1,1 | 0% | 4,4 | 4,4 | 1,1 | 1,1 | 1,1 | 1,1 | 1,1 | 3,3 | 3,3 | 37% |